Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Philip Mease, MD

Rheumatologist, Director of Rheumatology Research, Clinical Professor Director of Rheumatology Research Swedish Medical Center/Providence-St Joseph Health
Swedish Medical Center/Providence St. Joseph Health
Seattle, WA, United States

Dr. Mease received undergraduate and medical degrees from Stanford University, completed residency in internal medicine and fellowship in rheumatology at the University of Washington, directs the rheumatology research division at Swedish Medical Center/Providence St. Joseph Health and is Clinical Professor of Medicine at the University of Washington in Seattle. Research interests include psoriatic arthritis (PsA) and spondyloarthritis (SpA), including disease state, development of outcome measures, and determining the efficacy and safety of emerging therapies. He has authored over 650 journal articles, 1000 abstracts, and many book chapters. Expertscape designation: most published person in world on PsA and psoriasis. Founding organizer and current treasurer of the Group for Research and Assessment of Psoriasis and PsA (GRAPPA). Member of the Assessment of Spondyloarthritis international Society (ASAS) and the Spondyloarthritis Research and Treatment Network (SPARTAN). Active in the Outcome Measures in Rheumatology Clinical Trials (OMERACT) organization. Scientific director of PsA and SpA arms of the Consortium of Rheumatology Researchers of North America (Corrona/CorEvitas) registry. Awards: National Psoriasis Foundation 2019 lifetime achievement award for his work in advancing the field of PsA; Arthritis Foundation Legacy award; Rheumatology Winter Clinical Symposium Kahuna award for excellence in education.

Presentation(s):

  • FIT Program: Working At and with Industry as a Rheumatologist

    Friday, November 10, 2023
    12:55 PM – 1:40 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 0499: Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 0508: Assessment of Pain Outcomes in a Phase 2 Trial of a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, Deucravacitinib, in Patients with Active PsA

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 0509: Assessment of Direct and Indirect Impact on Pain and Fatigue Outcomes in a Phase 2 Clinical Trial of Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Patients with Active PsA: A Mediation Analysis

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 0510: Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 0511: Long-term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 1412: Improvements in Patient-Reported Outcomes Through 6 Months of Guselkumab Treatment in Patients with Active Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 1413: Effect of Apremilast Treatment on the Domains of MDA-Joints in Patients with Early Oligoarticular Psoriatic Arthritis: 16-Week Results from FOREMOST

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 1414: Effects of Apremilast on Changes in Cardiometabolic Parameters by Diabetes and Obesity Status in Patients with Psoriatic Arthritis

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 1415: Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD‑Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 223: TREMFYA® Efficacy, Safety, and Real-World Evidence with Subtitle: in Adults with Active Psoriatic Arthritis

    Monday, November 13, 2023
    1:30 PM – 2:15 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 1688: Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks

    Monday, November 13, 2023
    4:15 PM – 4:25 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)

  • 1691: 16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast

    Monday, November 13, 2023
    5:00 PM – 5:10 PM PT

    Disclosure(s): AbbVie: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Acelyrin: Consultant (Ongoing); Aclaris: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Boehringer Ingelheim: Consultant (Ongoing); Bristol Myers Squibb: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Galapagos: Consultant (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline: Consultant (Ongoing); Inmagene: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MoonLake Pharma: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Sun Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Ventyx: Consultant (Ongoing); Xinthera: Consultant (Ongoing)